Comparison of Speed of Onset of Platelet Inhibition After Loading Doses of Clopidogrel Versus Prasugrel in Healthy Volunteers and Correlation With Responder Status

      Failure to achieve an adequate level of platelet inhibition during percutaneous coronary intervention is associated with an increased risk for periprocedural myocardial injury. This study was conducted to compare the initial rate of platelet inhibition after a loading dose (LD) of prasugrel or clopidogrel and determine the association between the initial rate of inhibition and pharmacodynamic responder status. Data were pooled from 3 studies in which healthy subjects received LDs of prasugrel (60 mg; n = 76) or clopidogrel (300 mg; n = 87). Maximum platelet aggregation (MPA; 20 μmol/L adenosine diphosphate) was measured by turbidimetric aggregometry (0.25 to 24 hours after dosing). A mechanistic model was used to estimate the initial rate of decrease in MPA per hour (fast onset: MPA decrease >20%/hour). Subjects were defined as pharmacodynamic poor responders if the absolute decrease in MPA from baseline was <15% at either 4 to 5 or 24 hours after dosing. The median initial rate of decrease in MPA was greater after prasugrel (203%/hour) than with clopidogrel (23%/hour) (p <0.001). Overall, 76 subjects (100%) receiving prasugrel had fast onset of platelet inhibition compared with 47 subjects (54%) receiving clopidogrel. The initial rate of decrease in MPA was highly correlated with responder status (p <0.001). After prasugrel, subjects had a lower median MPA compared with clopidogrel (p <0.001; from >0.25 to 24 hours after dosing), and intersubject variability in MPA response was less after prasugrel compared with clopidogrel (p <0.001; from >1 to 24 hours after dosing). In conclusion, platelet inhibition after a 60-mg LD of prasugrel was more rapid in onset, less variable, and greater in magnitude than with a 300-mg LD of clopidogrel. After a thienopyridine LD, the initial rate of platelet inhibition was predictive of pharmacodynamic responder status.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Vorchheimer D.A.
        • Becker R.
        Platelets in atherothrombosis.
        Mayo Clin Proc. 2006; 81: 59-68
        • Niitsu Y.
        • Jakubowski J.A.
        • Sugidachi A.
        • Asai F.
        Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.
        Semin Thromb Hemost. 2005; 31: 184-194
        • Sugidachi A.
        • Asai F.
        • Ogawa T.
        • Inoue T.
        • Koikke H.
        The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
        Br J Clin Pharm. 2000; 129: 1439-1446
        • Matetzky S.
        • Shenkman B.
        • Guetta V.
        • Shecter M.
        • Bienart R.
        • Goldenberg I.
        • Novikov I.
        • Pres H.
        • Savion N.
        • Varon D.
        • Hod H.
        Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.
        Circulation. 2004; 109: 3171-3175
        • Muller I.
        • Seyfarth M.
        • Rudiger S.
        • Wolf B.
        • Pogatsa-Murray G.
        • Schomig A.
        • Gawaz M.
        Effect of high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement.
        Heart. 2001; 85: 92-93
        • Smith S.C.
        • Feldman T.E.
        • Hirshfeld J.W.
        • Jacobs A.K.
        • Kern M.J.
        • King III, S.B.
        • Morrison D.A.
        • O’Neill W.W.
        • Schaff H.V.
        • Whitlow P.L.
        • Williams D.O.
        • Task Force Members
        ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article.
        Circulation. 2005; 113: 156-175
        • Steinhubl S.R.
        • Berger P.B.
        • Brennen D.M.
        • Topol E.J.
        • CREDO Investigators
        Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention.
        J Am Coll Cardiol. 2006; 47: 939-943
        • Hochholzer W.
        • Trenk D.
        • Frundi D.
        • Blanke P.
        • Fischer B.
        • Andris K.
        • Bestehorn H.P.
        • Büttner H.J.
        • Neumann F.J.
        Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention.
        Circulation. 2005; 111: 2560-2564
        • Angiolillo D.J.
        • Fernandez-Ortiz A.
        • Bernardo E.
        • Ramirez C.
        • Sabate M.
        • Banuelos C.
        • Hernandez-Antolin R.
        • Escaned J.
        • Moreno R.
        • Alfonso F.
        • Macaya C.
        High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.
        Eur Heart J. 2004; 25: 1903-1910
        • Kandzari D.E.
        • Berger P.B.
        • Kastrati A.
        • Steinhubl S.R.
        • Mehilli J.
        • Dotzer F.
        • ten Berg J.M.
        • Neumann F.J.
        • Bollwein H.
        • Dirschinger J.
        • Schomig A.
        • ISAR-REACT Study Investigators
        Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
        J Am Coll Cardiol. 2004; 44: 2133-2136
        • Kastrati A.
        • von Beckerath N.
        • Joost A.
        • Pogatsa-Murray G.
        • Gorchakova O.
        • Schomig A.
        Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy.
        Circulation. 2004; 110: 1916-1919
        • Von Beckerath N.
        • Taubert D.
        • Pogasta-Muray G.
        • Schomig E.
        • Kastrati A.
        • Schomig A.
        Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel.
        Circulation. 2005; 112: 2946-2950
        • Montalescot G.
        • Sideris G.
        • Meuleman C.
        • Bal-dit-Sollier C.
        • Lellouche N.
        • Steg G.
        • Slama M.
        • Milleron O.
        • Collet J.P.
        • Henry P.
        • et al.
        • ALBION Trial Investigators
        A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes.
        J Am Coll Cardiol. 2006; 48 (931–w938)
        • Gurbel P.A.
        • Bliden K.P.
        • Hayes K.M.
        • Yoho J.A.
        • Herzog W.R.
        • Tantry U.S.
        The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.
        J Am Coll Cardiol. 2005; 45: 1392-1396
        • Jakubowski J.A.
        • Payne C.D.
        • Brandt J.T.
        • Weerakkody G.J.
        • Farid N.A.
        • Small D.S.
        • Naganuma H.
        • Li G.Y.
        • Winters K.J.
        The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.
        J Cardiovasc Pharmacol. 2006; 47: 377-384
        • Brandt J.T.
        • Payne C.D.
        • Wiviott S.D.
        • Weerakkody G.J.
        • Farid N.A.
        • Small D.S.
        • Jakubowski J.A.
        • Naganuma H.
        • Winters K.J.
        A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
        Am Heart J. 2007; 153: 66.e9-66.e16
      1. Weerakkody G, Brandt JT, Payne CD, Jakubowski JA, Naganuma H, Winters KJ. Clopidogrel poor responders: an objective definition based on Bayesian classification. Platelets. In press.

        • Daniel W.W.
        Applied Nonparametric Statistics. 2nd Ed. PWS-Kent, Boston, Massachusetts1990: 386-395
        • Jernberg T.
        • Payne C.D.
        • Winters K.J.
        • Darstein C.
        • Brandt J.T.
        • Jakubowski J.A.
        • Naganuma H.
        • Siegbahn A.
        • Wallentin L.
        Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
        Eur Heart J. 2006; 27: 1166-1173
        • Ross S.M.
        Introduction to Probability Models. 9th ed. Academic Press, San Diego, California2003: 200-203